Metastatic Solid Tumors
66
19
23
24
Key Insights
Highlights
Success Rate
83% trial completion
Published Results
13 trials with published results (20%)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 49/100
7.6%
5 terminated out of 66 trials
82.8%
-3.7% vs benchmark
2%
1 trials in Phase 3/4
54%
13 of 24 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 24 completed trials
Clinical Trials (66)
Study of RAS(ON) Inhibitors in Combination With Ivonescimab in Patients With Solid Tumors
First in Human Study of M6223
A Study to Evaluate the Safety, Pharmacokinetics, and Activity of RO7566802 as a Single Agent and in Combination With Atezolizumab in Participants With Locally Advanced or Metastatic Solid Tumors
NP137 Clinical and Biological Activities Assessment in Patients With Advanced/Metastatic Solid Tumors Treated by Standard Anti PD-1/PD-L1 Immunotherapies
BEACON-1: Study of AVZO-103 as a Single Agent and in Combination Therapy in Patients With Locally Advanced or Metastatic Urothelial Cancer or Other Solid Tumors (AVZO-103-1001)
A Study to Evaluate INCB177054 in Participants With Select Advanced or Metastatic Solid Tumors
A First-in-human Study of BGB-53038, a Pan-KRAS Inhibitor, Alone or in Combinations in Participants With Advanced or Metastatic Solid Tumors With KRAS Mutations or Amplification
Study of MK-0472 in Participants With Advanced/Metastatic Solid Tumors (MK-0472-001)
Study of QLS5308 in Patients With Advanced Solid Tumors
SLV-324 Treatment of Metastatic Solid Tumors
AVENTINE-1: Study of AVZO-1418 as a Single Agent and in Combination Therapy in Patients With Locally Advanced or Metastatic Solid Tumors (AVZO-1418-1001)
ADCX-020 for the Treatment of Patients With Locally Advanced or Metastatic Cancers
The Sarah Nanotechnology System for Treatment of Advanced Metastatic Solid Tumors Using Hyperthermia.
Phase Ia/Ib Study of CKD-512 Alone and in Combination With Pembrolizumab in Subjects With Advanced or Metastatic Solid Tumors
Platform Trial Evaluating Safety and Efficacy of Ezabenlimab Anti- PD-1 Based Combination Therapies in PD-(L)1 naïve and PD- (L)1 Pretreated Patient Populations With Advanced/Metastatic Solid Tumours
Image-Guided 125I Seed Implantation Plus Standard Systemic Therapy for Patients With Multiple Metastatic Lesions
Rare Tumor Focused Platform Study of Innovative Therapies and Technologies (PLATFORM2)
A Study to Evaluate the Safety of INCA33890 in Participants With Advanced or Metastatic Solid Tumors
Recombinant Interleukin-15 in Combination With Checkpoint Inhibitors Nivolumab and Ipilimumab in People With Refractory Cancers
A Study of DS3610a in Participants With Advanced Solid Tumor